NASDAQ:PTGX Protagonist Therapeutics (PTGX) Stock Price, News & Analysis → Forget Nvidia, buy this A.I. Stock Now (From InvestorPlace) (Ad) Free PTGX Stock Alerts $25.57 -0.54 (-2.07%) (As of 04/17/2024 ET) Add Compare Share Share Today's Range$25.35▼$26.3950-Day Range$25.57▼$32.1552-Week Range$13.72▼$33.34Volume517,565 shsAverage Volume718,478 shsMarket Capitalization$1.49 billionP/E RatioN/ADividend YieldN/APrice Target$36.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Protagonist Therapeutics alerts: Email Address Protagonist Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside40.8% Upside$36.00 Price TargetShort InterestBearish5.90% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$2.52 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom $1.18 to ($0.97) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.89 out of 5 starsMedical Sector635th out of 913 stocksPharmaceutical Preparations Industry275th out of 402 stocks 3.5 Analyst's Opinion Consensus RatingProtagonist Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageProtagonist Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.90% of the outstanding shares of Protagonist Therapeutics have been sold short.Short Interest Ratio / Days to CoverProtagonist Therapeutics has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Protagonist Therapeutics has recently increased by 0.58%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldProtagonist Therapeutics does not currently pay a dividend.Dividend GrowthProtagonist Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PTGX. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 7 people have searched for PTGX on MarketBeat in the last 30 days. This is a decrease of -61% compared to the previous 30 days.MarketBeat Follows4 people have added Protagonist Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Protagonist Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,522,342.00 in company stock.Percentage Held by InsidersOnly 5.00% of the stock of Protagonist Therapeutics is held by insiders.Percentage Held by Institutions98.63% of the stock of Protagonist Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Protagonist Therapeutics are expected to decrease in the coming year, from $1.18 to ($0.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Protagonist Therapeutics is -17.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Protagonist Therapeutics is -17.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProtagonist Therapeutics has a P/B Ratio of 4.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceForget Nvidia, buy this A.I. Stock NowForget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.Click here to see the details. About Protagonist Therapeutics Stock (NASDAQ:PTGX)Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Read More PTGX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PTGX Stock News HeadlinesApril 3, 2024 | insidertrades.comInsider Selling: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CEO Sells 25,000 Shares of StockApril 3, 2024 | finance.yahoo.comProtagonist Therapeutics Inc CEO Sells 25,000 SharesApril 17, 2024 | InvestorPlace (Ad)Forget Nvidia, buy this A.I. Stock NowForget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.April 1, 2024 | finance.yahoo.comShareholders have faith in loss-making Protagonist Therapeutics (NASDAQ:PTGX) as stock climbs 3.7% in past week, taking five-year gain to 135%March 27, 2024 | markets.businessinsider.comProtagonist Therapeutics Earns ‘Buy’ Rating on Strong Clinical Progress and Strategic PartnershipsMarch 18, 2024 | finanznachrichten.deProtagonist Therapeutics, Inc.: Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with TakedaMarch 15, 2024 | finance.yahoo.comPTGX Apr 2024 15.000 callMarch 15, 2024 | finance.yahoo.comPTGX Apr 2024 30.000 putApril 17, 2024 | InvestorPlace (Ad)Forget Nvidia, buy this A.I. Stock NowForget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.March 12, 2024 | bizjournals.comThe People's Market owner snaps up former Protagonist space in heart of NoDa for barMarch 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Protagonist Therapeutics on Strong Phase 2b Results and Strategic Phase 3 Dosing of JNJ-2113March 11, 2024 | markets.businessinsider.comStrong Buy Rating for Protagonist Therapeutics on JNJ-2113’s Promising Psoriasis Treatment Efficacy and Financial OutlookMarch 3, 2024 | finance.yahoo.comThis Just In: Analysts Are Boosting Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Outlook for This YearMarch 2, 2024 | finance.yahoo.comEarnings Update: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Just Reported And Analysts Are Boosting Their EstimatesMarch 1, 2024 | finance.yahoo.comProtagonist Therapeutics Full Year 2023 Earnings: Beats ExpectationsFebruary 29, 2024 | finance.yahoo.comWe're Not Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash BurnFebruary 28, 2024 | markets.businessinsider.comBuy Rating Affirmed for Protagonist Therapeutics on Strong Pipeline and Strategic PartnershipsFebruary 28, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Gritstone Oncology (GRTS), Protagonist Therapeutics (PTGX)February 25, 2024 | seekingalpha.comProtagonist Therapeutics: Why I Remain On Sidelines Despite Obvious PromiseFebruary 21, 2024 | finance.yahoo.comNew England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia VeraFebruary 20, 2024 | finance.yahoo.comProtagonist Therapeutics Reports Granting of Inducement AwardsFebruary 17, 2024 | finance.yahoo.comPTGX Mar 2024 25.000 callFebruary 15, 2024 | finance.yahoo.comSteven Cohen Adjusts Position in Protagonist Therapeutics IncFebruary 8, 2024 | msn.comProtagonist Pictures Ups Janina Vilsmaier, Mounia Wissinger, Strengthens Sales and Marketing DivisionsFebruary 8, 2024 | msn.comProtagonist Pictures Promotes Janina Vilsmaier & Mounia Wissinger; Bolsters Sales & Marketing Teams Ahead Of EFMFebruary 7, 2024 | finance.yahoo.comNew England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis StudyFebruary 2, 2024 | markets.businessinsider.comBuy Rating on Protagonist Therapeutics: Strategic Takeda Partnership and Rusfertide’s Market PotentialSee More Headlines Receive PTGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today4/17/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PTGX CUSIPN/A CIK1377121 Webwww.protagonist-inc.com Phone(510) 474-0170FaxN/AEmployees112Year FoundedN/APrice Target and Rating Average Stock Price Target$36.00 High Stock Price Target$38.00 Low Stock Price Target$32.00 Potential Upside/Downside+40.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.49) Trailing P/E RatioN/A Forward P/E Ratio21.67 P/E GrowthN/ANet Income$-78,960,000.00 Net MarginsN/A Pretax Margin-131.59% Return on Equity-27.49% Return on Assets-25.30% Debt Debt-to-Equity RatioN/A Current Ratio16.71 Quick Ratio16.71 Sales & Book Value Annual Sales$60 million Price / Sales24.84 Cash FlowN/A Price / Cash FlowN/A Book Value$5.84 per share Price / Book4.38Miscellaneous Outstanding Shares58,280,000Free Float55,361,000Market Cap$1.49 billion OptionableOptionable Beta2.01 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Dinesh V. Patel Ph.D. (Age 67)CEO, President, Secretary & Director Comp: $883.46kDr. Suneel K. Gupta Ph.D. (Age 65)Chief Development Officer Comp: $640.89kDr. Mark Smythe Ph.D. (Age 59)Founder & VP Technology Mr. Asif Ali (Age 50)Executive VP & Chief Financial Officer Mr. Mohammad Masjedizadeh Ph.D.Executive VP & Chief Technical OfficerMr. Matthew M. Gosling (Age 53)Executive VP & General Counsel Ms. Carena SpiveyHead of HR & Senior VP of Human ResourcesDr. Ashok Bhandari Ph.D. (Age 60)Executive VP & Chief Drug Discovery and Preclinical Development Officer Mr. Carter J. King (Age 53)Executive Vice President of Business Development Ms. Abha BommireddiExecutive Vice President of Portfolio & Program ManagementMore ExecutivesKey CompetitorsDynavax TechnologiesNASDAQ:DVAXEdgewise TherapeuticsNASDAQ:EWTXArdelyxNASDAQ:ARDXTaro Pharmaceutical IndustriesNYSE:TAROArcus BiosciencesNYSE:RCUSView All CompetitorsInsiders & InstitutionsHennion & Walsh Asset Management Inc.Bought 849 shares on 4/17/2024Ownership: 0.060%Los Angeles Capital Management LLCBought 21,673 shares on 4/5/2024Ownership: 0.053%Dinesh V Ph D PatelSold 25,000 sharesTotal: $707,750.00 ($28.31/share)Vanguard Group Inc.Sold 74,478 shares on 3/11/2024Ownership: 5.412%Dinesh V Ph D PatelSold 30,000 sharesTotal: $948,600.00 ($31.62/share)View All Insider TransactionsView All Institutional Transactions PTGX Stock Analysis - Frequently Asked Questions Should I buy or sell Protagonist Therapeutics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PTGX shares. View PTGX analyst ratings or view top-rated stocks. What is Protagonist Therapeutics' stock price target for 2024? 4 analysts have issued twelve-month price targets for Protagonist Therapeutics' shares. Their PTGX share price targets range from $32.00 to $38.00. On average, they expect the company's share price to reach $36.00 in the next year. This suggests a possible upside of 40.8% from the stock's current price. View analysts price targets for PTGX or view top-rated stocks among Wall Street analysts. How have PTGX shares performed in 2024? Protagonist Therapeutics' stock was trading at $22.93 at the start of the year. Since then, PTGX stock has increased by 11.5% and is now trading at $25.57. View the best growth stocks for 2024 here. When is Protagonist Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our PTGX earnings forecast. How were Protagonist Therapeutics' earnings last quarter? Protagonist Therapeutics, Inc. (NASDAQ:PTGX) posted its earnings results on Tuesday, February, 27th. The company reported $0.44 earnings per share for the quarter, beating analysts' consensus estimates of $0.05 by $0.39. The business earned $60 million during the quarter, compared to analyst estimates of $60 million. What ETFs hold Protagonist Therapeutics' stock? ETFs with the largest weight of Protagonist Therapeutics (NASDAQ:PTGX) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC).ALPS Medical Breakthroughs ETF (SBIO). What other stocks do shareholders of Protagonist Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include VBI Vaccines (VBIV), Viking Therapeutics (VKTX), ImmunoGen (IMGN), SCYNEXIS (SCYX), Energy Transfer (ET), Strongbridge Biopharma (SBBP), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX) and Sorrento Therapeutics (SRNE). When did Protagonist Therapeutics IPO? Protagonist Therapeutics (PTGX) raised $70 million in an initial public offering on Thursday, August 11th 2016. The company issued 5,800,000 shares at $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets acted as the underwriters for the IPO. Who are Protagonist Therapeutics' major shareholders? Protagonist Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.06%) and Los Angeles Capital Management LLC (0.05%). Insiders that own company stock include Asif Ali, David Y Liu, Dinesh V Ph D Patel, Suneel Gupta and William D Waddill. View institutional ownership trends. How do I buy shares of Protagonist Therapeutics? Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PTGX) was last updated on 4/17/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop 5 AI Stocks to Buy for 2024Market Moving TrendsOptions trading has suddenly become more reliable.Eagle PublishingTop 5 Tech Stocks to Buy for 2024Daily Market AlertsThe #1 Crypto for 2024InvestorPlaceThe Greatest Bull Market in Crypto History…Weiss Ratings[BUY ALERT] Our #1 A.I. Stock for AprilBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.